Van Lanschot Kempen Investment Management N.V. Grows Position in CME Group Inc. $CME

Van Lanschot Kempen Investment Management N.V. grew its stake in shares of CME Group Inc. (NASDAQ:CME) by 0.1% during the 1st quarter, Holdings Channel.com reports. The firm owned 98,304 shares of the financial services provider’s stock after acquiring an additional 91 shares during the period. Van Lanschot Kempen Investment Management N.V.’s holdings in CME Group were worth $26,079,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in CME. Berkshire Asset Management LLC PA purchased a new stake in shares of CME Group during the 1st quarter worth approximately $329,000. BI Asset Management Fondsmaeglerselskab A S raised its holdings in CME Group by 427.1% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 74,879 shares of the financial services provider’s stock worth $19,865,000 after purchasing an additional 60,672 shares during the last quarter. Wellington Management Group LLP boosted its position in CME Group by 370.5% during the first quarter. Wellington Management Group LLP now owns 2,653,957 shares of the financial services provider’s stock worth $704,068,000 after purchasing an additional 2,089,935 shares in the last quarter. Korea Investment CORP boosted its position in CME Group by 2.9% during the first quarter. Korea Investment CORP now owns 222,073 shares of the financial services provider’s stock worth $58,914,000 after purchasing an additional 6,186 shares in the last quarter. Finally, Aptus Capital Advisors LLC grew its holdings in CME Group by 6.9% in the first quarter. Aptus Capital Advisors LLC now owns 5,575 shares of the financial services provider’s stock valued at $1,479,000 after purchasing an additional 358 shares during the last quarter. 87.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at CME Group

In other news, Director William R. Shepard bought 256 shares of the firm’s stock in a transaction dated Wednesday, June 25th. The stock was acquired at an average price of $270.53 per share, for a total transaction of $69,255.68. Following the acquisition, the director owned 258,196 shares of the company’s stock, valued at $69,849,763.88. This trade represents a 0.10% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Daniel G. Kaye sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $282.42, for a total transaction of $141,210.00. Following the completion of the transaction, the director owned 3,668 shares in the company, valued at $1,035,916.56. The trade was a 12.00% decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Morgan Stanley boosted their price objective on shares of CME Group from $301.00 to $304.00 and gave the stock an “overweight” rating in a research report on Thursday, April 24th. Keefe, Bruyette & Woods lifted their price objective on CME Group from $265.00 to $273.00 and gave the stock a “market perform” rating in a research report on Thursday, April 24th. Wall Street Zen cut CME Group from a “hold” rating to a “sell” rating in a report on Sunday, July 13th. Barclays set a $298.00 price target on CME Group and gave the stock an “equal weight” rating in a report on Thursday, July 24th. Finally, Piper Sandler lifted their price objective on CME Group from $283.00 to $296.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 15th. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $261.93.

CME Group Price Performance

CME Group stock opened at $270.41 on Tuesday. CME Group Inc. has a 1 year low of $206.44 and a 1 year high of $290.79. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.02 and a current ratio of 1.02. The firm has a 50 day moving average price of $275.56 and a 200 day moving average price of $267.83. The company has a market cap of $97.45 billion, a price-to-earnings ratio of 26.18, a PEG ratio of 4.86 and a beta of 0.44.

CME Group (NASDAQ:CME) last announced its quarterly earnings results on Wednesday, July 23rd. The financial services provider reported $2.96 earnings per share for the quarter, beating analysts’ consensus estimates of $2.91 by $0.05. CME Group had a net margin of 58.48% and a return on equity of 14.60%. The company had revenue of $1.69 billion for the quarter, compared to analyst estimates of $1.68 billion. During the same quarter last year, the business earned $2.56 EPS. CME Group’s revenue for the quarter was up 10.4% on a year-over-year basis. Sell-side analysts predict that CME Group Inc. will post 10.49 earnings per share for the current year.

CME Group Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 25th. Shareholders of record on Tuesday, September 9th will be given a dividend of $1.25 per share. This represents a $5.00 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Tuesday, September 9th. CME Group’s payout ratio is 48.40%.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.